Key statistics
On Friday, United Therapeutics Corp (UTH:DUS) closed at 316.40, -3.95% below its 52-week high of 329.40, set on Aug 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 311.70 |
---|---|
High | 316.40 |
Low | 311.70 |
Bid | 314.60 |
Offer | 317.80 |
Previous close | 313.30 |
Average volume | 3.80 |
---|---|
Shares outstanding | 44.49m |
Free float | 43.67m |
P/E (TTM) | 16.23 |
Market cap | 15.71bn USD |
EPS (TTM) | 21.75 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 18:30 BST.
More ▼
Press releases
- United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever
- United Therapeutics Corporation to Present at Upcoming Investor Conferences
- United Therapeutics Corporation Reports Second Quarter 2024 Financial Results
- United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024
- United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
- United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
More ▼